Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PhenDC3 is a highly potent, selective bisquinolinium small-molecule stabilizer of G-quadruplex (G4) DNA and RNA. Developed by the Teulade-Fichou group at the CNRS and Institut Curie, PhenDC3 binds to telomeric and promoter G-rich sequences with nanomolar affinity, altering G4 topology through intercalation. In research settings, it is widely used as a benchmark G4-stabilizing probe to study G4-dependent biological processes, including transcription inhibition, telomere dysfunction, replication stalling, and the activation of the cGAS-STING innate immune pathway via micronuclei formation. It has also demonstrated potential in preclinical models of cancer, fungal infections, and sepsis-associated vascular injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PhenDC3.